<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated whether SPARCL1 played an essential role in <z:e sem="disease" ids="C0598935" disease_type="Neoplastic Process" abbrv="">tumor initiation</z:e>, formation and progression of colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we examined expression of SPARCL1 protein in the <z:mpath ids='MPATH_458'>normal</z:mpath> colorectal mucosa, adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa and primary and <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>In matched patients, we found that SPARCL1 was negative in the distant <z:mpath ids='MPATH_458'>normal</z:mpath> colorectal mucosa, weakly expressed in the adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa, strongly expressed in primary colorectal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> and slightly expressed in their <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A similar pattern was observed in the SPARCL1 expression from our series of non-matched <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>The strongest expression and highest frequency of the SPARCL1 protein were found in the primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, in the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, the frequency of SPARCL1 expression was significantly increased from the Dukes' A to Dukes' B <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and then decreased gradually from the Dukes' B to C and D <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>There was no difference in the intensity of SPARCL1 expression between the central areas and invasion margins of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, the SPARCL1 protein was more strongly expressed in the highly differentiated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> than the lower differentiated ones </plain></SENT>
<SENT sid="8" pm="."><plain>The patients with positive expression of SPARCL1 in their <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had worse prognosis than the patients with SPARCL1-negative ones, even after the analyses by Multivariate and Interaction method </plain></SENT>
<SENT sid="9" pm="."><plain>Expression of SPARCL1 protein might be a valuable biomarker for early diagnosis in <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> and further predicting patients' prognosis </plain></SENT>
</text></document>